Senators demand action as health insurers pay multiples more for generic drugs
- Health-care companies continue to see gains
- Senators call for investigation into high prices of generic drugs
- Health insurers paying multiples more for drugs than manufacturers charge
- Shares of cited companies rise
- FDA places clinical hold on Entrada Therapeutics’ drug candidate
Health-care companies continued to see mild gains as demand for defensive sectors remained strong. Senators Elizabeth Warren and Mike Braun have called on the federal government to investigate health insurers that are paying high prices for generic drugs used to treat serious diseases like cancer and multiple sclerosis. Recent reports have revealed that big health insurers such as Cigna Group, CVS Health, and UnitedHealth Group are paying significantly more for drugs like cancer therapy Gleevec and multiple-sclerosis treatment Tecfidera than what manufacturers charge for generic versions. As a result, shares of these companies have risen. In other news, Entrada Therapeutics saw a drop in its shares after the U.S. Food and Drug Administration refused to lift the clinical hold on the company’s planned study of its Duchenne muscular dystrophy drug candidate.
Public Companies: Cigna Group (Cigna), CVS Health (CVS), UnitedHealth Group (UNH)
Private Companies: Entrada Therapeutics
Key People: Sen. Elizabeth Warren (D., Mass.), Sen. Mike Braun (R., Ind.)
Factuality Level: 7
Justification: The article provides specific information about the call for a government investigation into health insurers paying high prices for generic drugs. It also mentions the recent report by The Wall Street Journal about big health insurers paying multiples more for certain drugs. However, the article lacks in-depth analysis and context, and it includes some tangential information about the rise of certain companies and the drop in shares of Entrada Therapeutics.
Noise Level: 3
Justification: The article provides relevant information about health-care companies and their pricing practices for generic drugs. It also mentions the response from Senators Warren and Braun. However, the article lacks in-depth analysis, scientific rigor, and actionable insights. It mainly reports on stock market movements and regulatory decisions without exploring the long-term trends or consequences of these events.
Financial Relevance: Yes
Financial Markets Impacted: Health-care companies
Presence of Extreme Event: No
Nature of Extreme Event: No
Impact Rating of the Extreme Event: No
Justification: The article discusses the demand for defensive sectors, specifically health-care companies. It also mentions a call by Senators to investigate health insurers paying high prices for generic drugs. However, there is no mention of an extreme event or its impact rating.
www.marketwatch.com 
